SAN DIEGO, Dec. 16, 2025 /PRNewswire/ — Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology today announced an update on the INBRX-106 Phase 2/3 clinical trial in combination…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
